Dissecting the role of GPR34 in cDC1 migration and function

剖析 GPR34 在 cDC1 迁移和功能中的作用

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT As critical mediators of immunity against intracellular pathogens and cancer, type 1 conventional dendritic cells (cDC1s) cross-present exogenous, cell-associated antigens to CD8+ T cells, facilitated by the colocalization of these two cell types in the T cell zone of secondary lymphoid tissues. This microanatomical organization is orchestrated by CCR7 and XCR1, two G protein-coupled receptors (GPCRs) on cDC1s that guide their migration towards gradients of chemoattractant ligand. Recent reports have established a crucial role for tumor-associated cDC1s in cancer immunity. However, the GPCRs mediating cDC1 recruitment and positioning at sites of inflammation and in tumors are incompletely understood. Preliminary work has revealed that GPR34, an understudied X-linked GPCR, is highly expressed by cDC1s, and in vitro studies have shown that this lysophosphatidylserine (lysoPS)-responsive receptor supports cell migration. Preliminary data presented herein indicate that GPR34 promotes the accumulation of cDC1s in the inflamed mouse peritoneal cavity (PerC) in a cell-intrinsic manner. The PerC is a clinically important site for colon and ovarian cancer metastasis. In a preliminary experiment inspired by the connection between cDC1 accumulation and cancer outcomes, GPR34-deficiency led to increased growth of a subcutaneous (SQ) tumor model. This proposal will test the hypothesis that GPR34 regulates cDC1 organization and function during inflammation and cancer. Aim 1 will mechanistically define how GPR34 controls the abundance, trafficking, and positioning of PerC cDC1s using a combination of techniques including in vivo kinetic immune phenotyping, in vitro migration assays, and immunofluorescence microscopy. Aim 2 will investigate the role of GPR34 and lysoPS in cancer immunity using ectopic SQ and PerC tumor models along with tools to study antigen-specific T cell responses and to manipulate ligand levels. Completion of these Aims will elucidate key mechanisms by which GPR34 on cDC1s influences the response to inflammation and malignancy, providing opportunities for the development of therapeutics that modulate the lysoPS-GPR34 chemoattractant system. These research goals will be conducted in conjunction with a comprehensive training plan to prepare the applicant for an independent career as an academic physician-scientist. Training includes rigorous mentorship in scientific skills from a highly qualified sponsor, Dr. Jason Cyster; technical education from postdoctoral fellows in the applicant’s lab and collaborating labs; seminars, journal clubs, workshops, and conferences; and clinically geared activities. Research and training will take place at the University of California, San Francisco, which offers a highly innovative and collaborative immunology research environment and an exceptional medical school for clinical training.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hanson Peter Tam其他文献

Hanson Peter Tam的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.98万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 3.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了